Dr. Rudin on Immunotherapy Biomarkers in Lung Cancer

Charles M. Rudin, MD, PhD
Published: Wednesday, Apr 25, 2018



Charles M. Rudin, MD, PhD, chief, Thoracic Oncology Service, co-director, Druckenmiller Center for Lung Cancer Research, Sylvia Hassenfeld Chair in Lung Cancer Research, Memorial Sloan Kettering Cancer Center, discusses biomarkers for immunotherapy in lung cancer.

The current biomarkers used to select for immunotherapy in lung cancer are not perfect, says Rudin, but they all enrich for the probability of response. PD-L1 and tumor mutation burden (TMB) are 2 of the markers that are often used, with TMB quickly becoming a popular choice.

It is hard to know how the field will play out in the future, Rudin says. If there is benefit in giving immunotherapy to patients who are biomarker negative, even if the relative benefit is smaller, there is good rationale for the use of immunotherapy in those populations––especially if these patients demonstrate durable responses with long-term progression-free survival.


Charles M. Rudin, MD, PhD, chief, Thoracic Oncology Service, co-director, Druckenmiller Center for Lung Cancer Research, Sylvia Hassenfeld Chair in Lung Cancer Research, Memorial Sloan Kettering Cancer Center, discusses biomarkers for immunotherapy in lung cancer.

The current biomarkers used to select for immunotherapy in lung cancer are not perfect, says Rudin, but they all enrich for the probability of response. PD-L1 and tumor mutation burden (TMB) are 2 of the markers that are often used, with TMB quickly becoming a popular choice.

It is hard to know how the field will play out in the future, Rudin says. If there is benefit in giving immunotherapy to patients who are biomarker negative, even if the relative benefit is smaller, there is good rationale for the use of immunotherapy in those populations––especially if these patients demonstrate durable responses with long-term progression-free survival.



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: ALK-Positive NSCLC: Emerging Strategies to Inform Sequencing, Optimize Outcomes, and Address Unmet Clinical Needs Along the Disease ContinuumAug 29, 20181.5
Community Practice Connections™: Oncogenic Tumor Board in Advanced NSCLC: Leveraging Actionable Mutations Along the Disease Continuum to Optimize Patient OutcomesAug 30, 20182.0
Publication Bottom Border
Border Publication
x